Cash position at €9.7 million with financing secured into early Q2 2027. Positive clinical and feasibility results for BioChaperone® programs drive ongoing pharma discussions, while development of M1Pram is paused and new platforms like AdoXLong™ and AdOral® advance.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.